Vaccines chief may have been cut out of White House-Pfizer loop on early trial data for Omicron-targeting booster, recalling White House making original booster decision. The FDA is getting feisty as a cascade of early research on the effectiveness of COVID-19 bivalent boosters, which were authorized without human data, intersects with embarrassing headlines about "rebound" infections for highly inoculated federal officials. Public health officials stand to get even more defensive amid revelations that Pfizer is sharing undisclosed booster efficacy data with the White House and that boosters may actually weaken immune systems' ability to fight COVID. Center for Biologics Evaluation...